Physician profile
Cheryl Gray
NPI 1316105943
$935.76
in general payments reported to CMS, 2019-2025
16 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.14 · 2022: $133 · 2023: $163 · 2024: $185 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.47 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.58 | 2022-2025 | |
| Lilly USA, LLC | $135.10 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $123.60 | 2025 | Tremfya |
| Genzyme Corporation | $71.12 | 2023 | |
| Celgene Corporation | $48.22 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $39.21 | 2025 | Valchlor |
| Pfizer INC. | $34.95 | 2022 | |
| Incyte Corporation | $29.83 | 2024 | Opzelura |
| Amgen INC. | $27.51 | 2024 | Otezla |
| Leo Pharma INC. | $27.28 | 2025 | Anzupgo |
| Dermavant Sciences, INC. | $23.49 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $20.90 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $19.67 | 2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $18.31 | 2025 | Dupixent |
| Botanix Sb INC | $17.84 | 2025 | Sofdra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.